Literature DB >> 22451515

L-ficolin and capsular polysaccharide-specific IgG in cord serum contribute synergistically to opsonophagocytic killing of serotype III and V group B streptococci.

Mioko Fujieda1, Youko Aoyagi, Kousaku Matsubara, Yasuhito Takeuchi, Wakae Fujimaki, Misao Matsushita, John F Bohnsack, Shinji Takahashi.   

Abstract

Group B streptococci (GBS; Streptococcus agalactiae) are the most common cause of neonatal sepsis and meningitis. Serotype-specific IgG antibody is known to protect neonates against GBS infections by promoting opsonophagocytosis. The L-ficolin-mediated lectin pathway of the complement is also a potential mechanism for opsonization of GBS, because L-ficolin activates the complement after binding to serotype Ib, III, V, VI, and VIII GBS. In the present study, we investigated how L-ficolin and serotype-specific IgG in cord sera contribute to opsonophagocytic killing of GBS. Neither L-ficolin nor serotype-specific IgG concentrations correlated with C3b deposition on serotype Ib and VI GBS, suggesting L-ficolin- and serotype-specific IgG-independent mechanisms of complement activation. The percentage of serotype VIII GBS killed was high regardless of the concentration of L-ficolin and IgG. In contrast, L-ficolin and serotype-specific IgG can each initiate C3b deposition on serotype III and V GBS and promote phagocytosis by polymorphonuclear leukocytes, but L-ficolin and serotype-specific IgG together promote opsonophagocytic killing to a greater extent than does either alone in vitro. This synergy was observed when serotype III-specific IgG concentrations were between 1 and 6 μg/ml and when serotype V-specific IgG concentrations were between 2 and 5 μg/ml. Concentrations of serotype III-specific IgG in cord blood above 7 μg/ml are considered protective for neonates colonized with GBS, but most neonates with IgG levels of less than 7 μg/ml do not develop GBS infections. The data presented here suggest that L-ficolin enhances opsonophagocytosis of serotype III and V GBS when serotype-specific IgG alone is suboptimal for protection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451515      PMCID: PMC3370578          DOI: 10.1128/IAI.06232-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Correlation of phylogenetic lineages of group B Streptococci, identified by analysis of restriction-digestion patterns of genomic DNA, with infB alleles and mobile genetic elements.

Authors:  Shinji Takahashi; Shauna Detrick; April A Whiting; Anne J Blaschke-Bonkowksy; Youko Aoyagi; Elisabeth E Adderson; John F Bohnsack
Journal:  J Infect Dis       Date:  2002-09-13       Impact factor: 5.226

2.  Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen.

Authors:  Feng-Ying C Lin; Leonard E Weisman; Parvin H Azimi; Joseph B Philips; Penny Clark; Joan Regan; George G Rhoads; Carl E Frasch; Barry M Gray; James Troendle; Ruth A Brenner; Patricia Moyer; John D Clemens
Journal:  J Infect Dis       Date:  2004-07-28       Impact factor: 5.226

3.  Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci.

Authors:  Q Cheng; B Carlson; S Pillai; R Eby; L Edwards; S B Olmsted; P Cleary
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 4.  Ficolins: complement-activating lectins involved in innate immunity.

Authors:  Misao Matsushita
Journal:  J Innate Immun       Date:  2009-07-24       Impact factor: 7.349

5.  Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study.

Authors:  F Y Lin; J B Philips; P H Azimi; L E Weisman; P Clark; G G Rhoads; J Regan; N F Concepcion; C E Frasch; J Troendle; R A Brenner; B M Gray; R Bhushan; G Fitzgerald; P Moyer; J D Clemens
Journal:  J Infect Dis       Date:  2001-08-31       Impact factor: 5.226

6.  Trend of neonatal group B streptococcal infection during the last 15 years.

Authors:  Kiyoshi Hoshina; Yoko Suzuki; Hiroshi Nishida; Kazuhiko Kaneko; Seiji Matsuda; Masumi Kobayashi; Nobuaki Kadoi
Journal:  Pediatr Int       Date:  2002-12       Impact factor: 1.524

7.  Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine.

Authors:  Carol J Baker; Marcia A Rench; Pamela McInnes
Journal:  Vaccine       Date:  2003-07-28       Impact factor: 3.641

Review 8.  The role of ficolins in innate immunity.

Authors:  Misao Matsushita; Teizo Fujita
Journal:  Immunobiology       Date:  2002-09       Impact factor: 3.144

9.  Multilocus sequence typing system for group B streptococcus.

Authors:  Nicola Jones; John F Bohnsack; Shinji Takahashi; Karen A Oliver; Man-Suen Chan; Frank Kunst; Philippe Glaser; Christophe Rusniok; Derrick W M Crook; Rosalind M Harding; Naiel Bisharat; Brian G Spratt
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

10.  Seroepidemiologic studies of serotype VIII group B Streptococcus in Japan.

Authors:  Kousaku Matsubara; Kazuaki Katayama; Kunizo Baba; Hiroyuki Nigami; Hidekazu Harigaya; Masako Sugiyama
Journal:  J Infect Dis       Date:  2002-08-16       Impact factor: 5.226

View more
  10 in total

1.  Blood collection tubes influence serum ficolin-1 and ficolin-2 levels.

Authors:  Allison M Brady; Brady L Spencer; Ann R Falsey; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

2.  Human Cervical Mucus Plugs Exhibit Insufficiencies in Antimicrobial Activity Towards Group B Streptococcus.

Authors:  Jay Vornhagen; Phoenicia Quach; Verónica Santana-Ufret; Varchita Alishetti; Alyssa Brokaw; Blair Armistead; Hai Qing Tang; James W MacDonald; Theo K Bammler; Kristina M Adams Waldorf; Niels Uldbjerg; Lakshmi Rajagopal
Journal:  J Infect Dis       Date:  2018-04-23       Impact factor: 5.226

Review 3.  Intrinsic Maturational Neonatal Immune Deficiencies and Susceptibility to Group B Streptococcus Infection.

Authors:  Michelle L Korir; Shannon D Manning; H Dele Davies
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

4.  Rapid and efficient purification of ficolin-2 using a disposable CELLine bioreactor.

Authors:  K Aaron Geno; Brady L Spencer; Moon H Nahm
Journal:  J Immunol Methods       Date:  2015-05-30       Impact factor: 2.303

5.  Role of ficolin-A and lectin complement pathway in the innate defense against pathogenic Aspergillus species.

Authors:  Stefan Bidula; Hany Kenawy; Youssif M Ali; Darren Sexton; Wilhelm J Schwaeble; Silke Schelenz
Journal:  Infect Immun       Date:  2013-03-11       Impact factor: 3.441

6.  Serum opsonin ficolin-A enhances host-fungal interactions and modulates cytokine expression from human monocyte-derived macrophages and neutrophils following Aspergillus fumigatus challenge.

Authors:  Stefan Bidula; Darren W Sexton; Silke Schelenz
Journal:  Med Microbiol Immunol       Date:  2015-09-04       Impact factor: 3.402

7.  The Group B Streptococcus-Secreted Protein CIP Interacts with C4, Preventing C3b Deposition via the Lectin and Classical Complement Pathways.

Authors:  Giampiero Pietrocola; Simonetta Rindi; Roberto Rosini; Scilla Buccato; Pietro Speziale; Immaculada Margarit
Journal:  J Immunol       Date:  2015-11-25       Impact factor: 5.422

8.  Defining the interaction of the protease CpaA with its type II secretion chaperone CpaB and its contribution to virulence in Acinetobacter species.

Authors:  Rachel L Kinsella; Juvenal Lopez; Lauren D Palmer; Nichole D Salinas; Eric P Skaar; Niraj H Tolia; Mario F Feldman
Journal:  J Biol Chem       Date:  2017-10-05       Impact factor: 5.157

Review 9.  Activated Complement Factors as Disease Markers for Sepsis.

Authors:  Jean Charchaflieh; Julie Rushbrook; Samrat Worah; Ming Zhang
Journal:  Dis Markers       Date:  2015-09-02       Impact factor: 3.434

10.  Implication of TLR- but not of NOD2-signaling pathways in dendritic cell activation by group B Streptococcus serotypes III and V.

Authors:  Paul Lemire; David Roy; Nahuel Fittipaldi; Masatoshi Okura; Daisuke Takamatsu; Eugenia Bergman; Mariela Segura
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.